The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Dysport (abobotulinumtoxin A) for the treatment of upper limb spasticity in children with cerebral palsy. This follows its ... Read more
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.